Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung

Chausovsky, Genady; Luchansky, Michael; Figer, Arié; Shapira, Jeremiah; Gottfried, Maya; Novis, B. H.; Bogelman, Galina; Zemer, Ruth; Zimlichman, Shulamit; Klein, Ami

doi:10.1002/(sici)1097-0142(19991201)86:11<2398::aid-cncr30>3.0.co;2-5

Cited by 65 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, this finding fits with other studies that have shown the presence of CTCs in patients with all stages of PDAC and not only metastatic cancer. 11,13,24 The association of CTCs with survival remained significant by multivariate analysis even when accounting for traditional prognostic factors such as positive margin and grade, suggesting that epithelial CTCs may be useful as an independent prognostic factor before resection to identify patients with more aggressive tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have demonstrated the presence of CTCs in the blood of patients with all stages of PDAC, not only patients with metastatic disease, indicating CTCs as a possible source of and not only a result of metastatic disease. 11,13,23–27 In addition, several studies have found an association between the presence of CTCs and poorer survival. 23,25 Our study investigated the prognostic significance of phenotypic subtypes of CTCs.…”

Section: Discussionmentioning

confidence: 99%

“…10–13 Several studies have identified CTCs as a potential minimally invasive mechanism to analyze a patient’s primary tumor and their subsequent risk of developing metastasis. 14–17 CTCs have been identified in the blood of many patients with malignant neoplasms, but only rarely in healthy controls.…”

mentioning

confidence: 99%

“…10,22 CTCs have been identified in the blood of patients with all stages of PDAC, and previous studies have found an association between the presence of CTCs and poorer survival. 11,13,23–27 However, most studies have identified CTCs using the epithelial marker cytokeratin, with only limited reports of further phenotypic characteristics of CTCs in PDAC. 27,28 …”

mentioning

confidence: 99%

See 3 more Smart Citations

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

et al. 2016

View full text Add to dashboard Cite

Objective We assessed circulating tumor cells (CTCs) with epithelial and mesenchymal phenotypes as a potential prognostic biomarker for patients with pancreatic adenocarcinoma (PDAC). Background PDAC is the fourth leading cause of cancer death in the United States. There is an urgent need to develop biomarkers that predict patient prognosis and allow for better treatment stratification. Methods Peripheral and portal blood samples were obtained from 50 patients with PDAC before surgical resection and filtered using the Isolation by Size of Epithelial Tumor cells method. CTCs were identified by immunofluorescence using commercially available antibodies to cytokeratin, vimentin, and CD45. Results Thirty-nine patients (78%) had epithelial CTCs that expressed cytokeratin but not CD45. Twenty-six (67%) of the 39 patients had CTCs which also expressed vimentin, a mesenchymal marker. No patients had cytokeratin-negative and vimentin-positive CTCs. The presence of cytokeratin-positive CTCs (P < 0.01), but not mesenchymal-like CTCs (P = 0.39), was associated with poorer survival. The presence of cytokeratin-positive CTCs remained a significant independent predictor of survival by multi-variable analysis after accounting for other prognostic factors (P < 0.01). The detection of CTCs expressing both vimentin and cytokeratin was predictive of recurrence (P = 0.01). Among patients with cancer recurrence, those with vimentin-positive and cytokeratin-expressing CTCs had decreased median time to recurrence compared with patients without CTCs (P = 0.02). Conclusions CTCs are an exciting potential strategy for understanding the biology of metastases, and provide prognostic utility for PDAC patients. CTCs exist as heterogeneous populations, and assessment should include phenotypic identification tailored to characterize cells based on epithelial and mesenchymal markers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…One early study by Chausovsky et al looked at a combination of density gradient enrichment followed by nested RT-PCR amplification of CK-20 mRNA in 28 consecutive PC patients [46]. They were able to amplify CK-20 in 22/28 (78.6%) patients.…”

Section: Studies Of Ctcs In Pancreatic Cancermentioning

confidence: 99%

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Court

Ankeny

Hou

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the fourth most common cause of cancer-related death in the USA, primarily due to late presentation coupled with an aggressive biology. The lack of adequate biomarkers for diagnosis and staging confound clinical decision-making and delay potentially effective therapies. Circulating tumor cells (CTCs) are a promising new biomarker in PC. Preliminary studies have demonstrated their potential clinical utility, and newer CTC isolation platforms have the potential to provide clinicians access to tumor tissue in a reliable, real-time manner. Such a ‘liquid biopsy’ has been demonstrated in several cancers, and small studies have demonstrated its potential applications in PC. This article reviews the available literature on CTCs as a biomarker in PC and presents the latest innovations in CTC research as well as their potential applications in PC.

show abstract

Tumour cell dissemination following endoscopic stent insertion

Maruthachalam

Lash

Shenton

et al. 2007

British Journal of Surgery

245

137

View full text Add to dashboard Cite

show abstract

Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung

Cited by 65 publications

References 10 publications

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma

Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis

Tumour cell dissemination following endoscopic stent insertion

Contact Info

Product

Resources

About